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Evaluation of glutathione S-transferase Pi in non-invasive ductal
carcinoma of breast
C.O.C. Bellamy & D.J. Harrison
Department of Pathology, University Medical School, Edinburgh, UK.
Summary Glutathione S-transferase Pi (GST P) has been reported to be a marker of dysplastic lesions. For
this reason expression of GST P by intraduct breast carcinoma was evaluated by immunohistochemistry.
Thirty-seven of 92 carcinomas (40%) were GST P positive. GST P staining did not correlate with histological
variables, c-erbB-2 overexpression or with clinical outcome. The GST P status of recurrences did not correlate
with that of the index lesion. There is little evidence that GST P is a useful marker of the potential of intraduct
breast carcinoma to become invasive.
The GSTs are a multigene family of intracellular proteins
currently categorised into four cytosolic classes (called
GST A, M, P and T) and microsomal GST (Mannervik et
al., 1992). They play a major role in prevention of cell injury
through catalysing detoxification reactions for a wide variety
of endogenous and exogenous cytotoxins, including chemo-
therapeutic agents (Mannervik, 1985). The GSTs have an
additional but less well-characterised function as intracellular
binding proteins and may act as intracellular transport
molecules for non-polar compounds, including steroid hor-
mones (Boyer, 1989). GST P is a marker of preneoplasia in
animal models of carcinogenesis (Kitahara et al., 1984), and
GSTP expression is altered in early and advanced human
neoplasia. It has been described as a marker for dysplastic
lesions of cervix, oesophagus and colon and for intratubular
germ cell neoplasia in the testis (Shiratori et al., 1987; Sato,
1989; Kodate et al., 1986; Klys et al., 1992). However, the
specificity of this is in doubt since GST P expression is also
increased in certain non-neoplastic epithelial proliferations,
e.g. cervical viral warts (Carder et al., 1990). A wide variety
of invasive carcinomas show increased GSTP expression
(Howie et al., 1990), although this is not a universal
phenomenon (Harrison, 1993).
GST P is the major GST class in breast cancers and it is
overexpressed in a subclass of oestrogen receptor-poor car-
cinomas (Howie et al., 1989). The implications for therapy
are highlighted by data from a breast carcinoma cell line
showing that increased GST expression and loss of oestrogen
receptors occurs during acquisition of a multidrug-resistant
phenotype (Moscow et al., 1988; Vickers et al., 1988). How-
ever the clinical value of these observations has yet to be
tested. A recent immunohistochemical study of 74 cases of
invasive breast carcinoma has shown heterogeneity of GST
staining, but whether this is related to intrinsic drug resis-
tance is not known (Cairns et al., 1992). The results of that
study indicated that GST P expression is negatively cor-
related with increasing grade of carcinoma.
There is, however, no published information on GST ex-
pression by intraduct breast carcinoma (ductal carcinoma in
situ, DCIS), which represents the earliest morphologically
recognisable form of breast carcinoma and from which
invasive carcinoma may develop. The present short study
aimed to analyse GST P expression by immunohistochemis-
try of a series of 92 patients with DCIS, for all of whom
follow-up findings were available. The findings are correlated
with the carcinoma histology, including grade and mor-
phological pattern, and also with the clinical outcome and
with GST P expression in recurrent and metastatic car-
cinomas that developed. Correlation is also made with
overexpression of the c-erbB-2 gene product as assessed by
immunohistochemistry.
Patients and methods
Ninety-two women with DCIS without previous breast car-
cinoma were studied. These patients represent part of a larger
cohort of DCIS patients reported in detail elsewhere
(Bellamy et al., 1993) and for whom material was available.
Follow-up data were available for all patients.
The tissue was formalin fixed and paraffin embedded and
one block was selected from each case. Serial 4 iLm sections
were cut, and one section was stained with haemotoxylin-
eosin to confirm the presence of carcinoma in the study
material. In cases of recurrence, blocks were also selected
from the recurrent carcinoma and, where present, from
lymph node metastases.
All immunohistochemistry was performed using a standard
peroxidase-anti-peroxidase technique. Negative controls
were prepared by omitting the primary antibody. Staining for
GST P was carried out as described previously (Klys et al.,
1992) using a polyclonal rabbit antibody, which was a kind
gift from G.J. Beckett, University Department of Clinical
Biochemistry, Edinburgh, UK. Liver was used as a positive
control in which bile ducts stained positively.
GST staining was assessed semiquantitatively and each
tumour was categorised according to one of the following
staining patterns: none, focal, diffuse weak, diffuse strong.
Focal staining required unambiguously positive staining in at
least 10% of carcinoma cells. Tumours that showed only
equivocal staining of carcinoma cells were classified as GST P
negative since down-regulation of GST P compared with nor-
mal epithelium had clearly occurred. However, inclusion of
those tumours as GST P positive did not alter the con-
clusions from analysis of the results. Staining for overexpres-
sion of the c-erbB-2 gene product was carried out using the
rabbit polyclonal antiserum 21N at a final concentration of
3.3 tg ml-' (Gusterson et al., 1987). Tumours were scored as
c-erbB-2 positive when more than 5% of carcinoma cells
showed positive membrane staining. A known c-erbB-2-
positive invasive breast carcinoma was used as the positive
control.
Other variables assessed included the extent of breast
affected by carcinoma, categorised as single or multiquadrant
disease (mastectomy patients only), the predominant his-
tological pattern of DCIS (categorised as solid, comedo,
cribriform or micropapillary), the presence of luminal nec-
rosis and the nuclear grade (defined as grade 1 to 3 in order
of increasing pleomorphism, as for invasive carcinoma; Els-
ton, 1987).
Results
The age of the patients ranged from 29 to 71 years (average
55 years). Staining for GST P localised to both nucleus and
cytoplasm in most cases. Strong staining of benign epithe-
lium, including myoepithelial cells, was consistently observed
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within ducts and lobular units, acting as an internal positive
control (Figure 1). A minority of normal duct epithelial cells
showed unambiguous but weaker positive staining, of similar
intensity to the 'diffuse weak' staining category for carcinoma
cells. Staining of fibroblasts and inflammatory cells was
variable but occasionally strong and widespread. For the
purposes of analysis the three categories of GST P staining
(focal, diffuse weak, diffuse strong) were regarded as GST P
positive, however analyses comparing each individual cate-
gory of GST P staining with all other categories did not yield
any new correlations. Overall, 37 of 92 (40%) DCIS patients
were GST P positive (Figure 2). Table I correlates the result
for GST P expression with DCIS histological variables and
with c-erbB-2 status. It is apparent that cribriform DCIS was
most often GST P positive (15 of 28 cases; 54%) and micro-
papillary DCIS was least often positive (two of nine cases;
22%), however these differences in expression were not statis-
tically significant. GST P staining did not correlate sig-
nificantly with nuclear grade [positive case for grade 1, 8/19
(42%); grade 2, 18/38 (47%); grade 3, 13/35 (37%)], or with
the presence of necrosis [25/68 (37%) cases with necrosis
GST P positive; 12/24 (50%) cases without necrosis GST P
positive], or with the extent of breast affected by DCIS
[single and multiquadrant DCIS were GST P positive in 21/
52 (40%) cases and 5/10 (50%) cases respectively]. There was
no correlation between GST P expression and the c-erbB-2
status of the carcinomas (Table I).
Table II shows the patients who experienced recurrence
after median follow-up of 60 months (range 12-180 months).
Five patients had recurrence of DCIS only and five
developed invasive ductal carcinoma, including one case of
microinvasive carcinoma and two patients with regional
lymph node metastases. All recurrences followed high-grade
DCIS (grade 2 or 3), usually of comedo pattern. The
numbers are too small for meaningful analysis but there was
no consistent relationship to GST P expression. Of note is
that GST P expression in the recurrent DCIS did not always
relate to the GST status of the index lesion, and in one case
invasive carcinoma in the recurrence expressed GST P while
GST was absent in the antecedent DCIS lesion.
Discussion
There are no previous data on GST expression in non-
invasive breast carcinoma. The present study of a large
number of patients has demonstrated loss of GST P expres-
sion in DCIS when compared with normal breast epithelium.
These results differ from those in other epithelia in which
GST P expression is increased in dysplasia and in carcinoma
compared with normal cells (Sato, 1989; Howie et al., 1990).
The results presented here also indicate that loss of GST
expression can occur at a relatively early (i.e. intraepithelial)
stage in breast carcinogenesis, but that this loss is not an
irreversible event, as evidenced by altered GST P status in
some recurrences. The stimulus for such a reversal is not
evident from this study; no patient received adjuvant
chemotherapy.
The proportion of DCIS patients showing GST staining
(40%) is similar to that for invasive carcinoma, in that 47%
of invasive ductal carcinomas have been reported to express
GST P (Cairns et al., 1992). A DCIS lesion is most likely to
develop into invasive carcinoma if it is of high nuclear grade
and particularly when of comedo pattern (Bellamy et al.,
a
b
Figure 1 GST P staining in a benign breast lobule. There is
staining of both myoepithelial and epithelial cells. Note the stain-
ing of occasional parenchymal cells (bar = 85 nm).
Figure 2 a, Cribriform DCIS showing strong diffuse staining for
GST P (bar = 85 jLm). b, Comedo DCIS with luminal necrosis
and microcalcification. There is focal staining for GST P within
carcinoma cells although most of the malignant cells are negative
(bar = 85 fLm).
Table I Correlation of GST P expression with DCIS histological indices and c-erbB-2 status
DCIS pattern Nuclear grade Necrosis c-erbB-2
GST P status Comedo Solid Micropapillary Cribriform GI G2 G3 Present Absent + - Total
Diffuse strong 9 4 1 1 1 6 8 13 2 6 9 15
Diffuse weak 2 1 0 9 4 5 3 5 7 3 9 12
Focal 3 1 1 5 2 6 2 8 2 2 8 10
Negative 24 11 7 13 12 21 22 43 12 23 32 55
Total 38 17 9 28 19 38 35 69 23 34 58 92 cases
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Table II GST P expression in patients with recurrence
GST P in GSTP in recurrences
index lesion DCIS Invasive Metastatic
* - 0
-
--N/-----------------0
o-0 0O -
o-0 0-0
-
0 denotes negative staining fcor OST P. * denotes positive staining
for GST P. aMicroinvasive foci not present on recuts of archival tissue.
1993). The present results have shown no significant
difference in GST P status between high- and low-grade
DCIS or between comedo and other DCIS patterns. Further-
more, both GST-positive and GST-negative DCIS patients
developed invasive carcinoma in this study. Hence, GSTP
has not been found to be a marker for tumour progression in
DCIS. The lack of correlation between GSTP expression
and c-erbB-2 positivity in DCIS matches the findings in
invasive breast carcinoma (Cairns et al., 1992).
In conclusion, the results of this study indicate that assess-
ment of GSTP staining in non-invasive breast carcinoma
does not have a clinical utility. It is evident that GSTP
should not be regarded as a general marker of epithelial
preneoplasia since it may be expressed in both mor-
phologically normal epithelia (e.g. breast) and in non-
neoplastic proliferations (e.g. cervical viral warts; Carder et
al., 1990). The strong expression of GST P by benign
Figure 3 Invasive ductal carcinoma following DCIS. Note the
negative staining for GST P by islands of infiltrating carcinoma
cells in contrast with the strong parenchymal cell positivity
(bar = 35 1tm).
epithelial and stromal cells in breast (Figure 3) should be
remembered when interpreting biochemical analyses of tissue
homogenates, which fail to discriminate these from car-
cinoma cells. GST P is expressed in a number of proliferating
tissues, e.g. basal layer of cervix (Carder et al., 1990). Its
expression in some cases of DCIS may simply reflect an
abnormality of cell proliferation control in these cells and as
such is not necessarily related to aggressiveness or resistance
to therapy.
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